Neurocrine Biosciences (NBIX) Tops Q1 EPS by 13c; reaffirms guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $145.35 -0.51%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.20, $0.13 better than the analyst estimate of $1.07. Revenue for the quarter came in at $515.3 million versus the consensus estimate of $512.36 million.
GUIDANCE
INGREZZA Net Product Sales of $2,100- $2,200M
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
- Viper Energy (VNOM) Tops Q3 EPS by 3c
- Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
